Leukemia & Lymphoma Society

blood cells

The partnership with IAMI and the University of Kansas has helped the Leukemia & Lymphoma Society and its collaborators advance promising new treatments to patients in need.

The LLS Therapy Acceleration Program (TAP) exists to advance the diagnosis and treatment of blood cancers through continued funding of academic research, the therapy acceleration program and other special initiatives. Additionally, we proactively establish a research agenda and direct a portion of research spending to specific areas of unmet medical need for leukemia, lymphoma & myeloma.

TAP also participates directly in blood cancer therapy development by expanding research beyond academic collaborations and biotech partnerships to include pharmaceutical companies and/or venture capitalists.

Learn more about the Leukemia & Lymphoma Society.

Last modified: Jan 26, 2016

LLS logoThe Leukemia & Lymphoma Society (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families.

LLS funds lifesaving blood cancer research around the world and provides free information and support services.

Learn more about LLS